Clinical cancer advances in research are featured in this year’s 2021 ASCO report reflect progress in a range of cancers and across prevention and treatment.
Highlights in the Report Cancer Advances:
- Molecular Profiling Drives Progress in GI Cancers.
- Antibody-Drug Conjugate Shows Promise in GI Cancers.
- Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With DNA Mismatch Repair Deficiency.
- Progress in bringing targeted therapies to patients with earlier-stage disease.
- Biomarker-driven treatment approaches that offer more personalized care for lung, colorectal, and gastric cancers.
- Combinations of different therapies that extend survival without increasing toxicity.
- A growing number of targeted therapies are offering extended survival for more patients with difficult-to-treat cancers.
Research Priorities in Clinical Cancer for 2021
- Develop and Integrate Artificial Intelligence and Deep Learning in Cancer Research
- Identify Strategies That Predict Response and Resistance to Immunotherapies
- Optimize Multimodality Treatment for Solid Tumors
- Increase Precision Medicine Research and Treatment Approaches in Pediatric and Other Rare Cancers
- Optimize Care for Older Adults With Cancer
- Increase Equitable Access to Cancer Clinical Trials
- Reduce Adverse Consequences of Cancer Treatment
- Reduce Obesity’s Impact on Cancer Incidence and Outcomes
- Better Identify Potentially Malignant Lesions and Predict When Treatment is Needed
Problems in Clinical Cancer 2021
The COVID-19 public health emergency threatens to reverse years of momentum in cancer research. Laboratories conducting cancer research have closed or space has been redirected to COVID-19 research. Clinical trials and cancer advances have halted or slowed, creating a costly loss in research progress and delays in patient access to potentially life-saving treatments.